Hans E. Bishop

Hans E. Bishop is a prominent figure in the biotechnology sector, recognized for his significant contributions as an executive and investor. He co-founded Altos Labs, a company dedicated to cellular rejuvenation programming to reverse disease, injury, and the disabilities that can occur throughout life. Under his leadership, Altos Labs has attracted substantial investment, focusing on advancing regenerative medicine and cellular therapies. Prior to his role at Altos Labs, Bishop served as the Chief Executive Officer of Juno Therapeutics, a company specializing in immunotherapies for cancer treatment. His tenure at Juno was marked by strategic growth and the development of innovative therapies. Before Juno, he held various leadership positions, including Executive Vice President and Chief Operating Officer at Dendreon, and President of Specialty Medicine at Bayer HealthCare. His extensive experience spans across multiple facets of the biotechnology and pharmaceutical industries. Bishop's investment approach is characterized by a focus on high-impact, innovative companies within the healthcare and biotechnology sectors. He seeks to identify and support ventures that have the potential to transform medical treatments and improve patient outcomes. His strategic vision and leadership have been instrumental in the success and growth of the companies he has been associated with, reflecting his commitment to advancing medical science and healthcare solutions.

Innovative healthcare solutions, Strong management teams, Scalable business models, Potential for significant impact on patient care, Alignment with regenerative medicine and cellular therapy advancements